3SBio Inc. (01530) said the clinical trial application of the group's HIF-117 Capsule (SSS17) has been approved by the National Medical Products Administration on 12 November 2019. The group is currently actively preparing for initiating the clinical trial of such product.
HIF-117 Capsule is a selective small molecule inhibitor to hypoxia inducible factor proline hydroxylase (HIF-PH).
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情
